BTG Launches Radiopaque Embolic Bead in US Market.
M2 PHARMA-April 1, 2016-BTG Launches Radiopaque Embolic Bead in US Market
(C)2016 M2 COMMUNICATIONS
- UK-based specialist healthcare company BTG plc (LSE: BTG) has launched LC Bead Lumi in the US, a radiopaque embolic bead for the embolisation of hypervascular tumors and arteriovenous malformations, the company said.
LC Bead Lumi is a next generation development of LC Bead.
According to the company, the unique visibility of LC Bead Lumi during and after embolisation supports the optimisation of patient treatment by enabling real-time visible confirmation of bead location during the procedure.
This provides interventional radiologists more control, while at the same time facilitating discovery of regions of under-treatment, allowing precise evaluation of the completeness of tumor treatment and enhanced end-point determination, with long-lasting radiopacity to support follow-up management.
LC Bead Lumi has been developed on the same technology platform and to the same high standard as LC Bead, building upon its market leading clinical performance.
This launch represents the first market commercialisation for LC Bead Lumi, with regulatory clearances and launches planned for additional radiopaque bead products worldwide.
((Comments on this story may be sent to email@example.com))
|Printer friendly Cite/link Email Feedback|
|Date:||Apr 1, 2016|
|Previous Article:||UK National Institute of Health Provides Positive Guidance on electroCore's gammaCore Migraine Treatment.|
|Next Article:||Array BioPharma collaborates with Asahi Kasei Pharma.|